)
Overview
<ul>
<li>BioAtla Q3 net loss widens to $15.8 mln, driven by absence of collaboration revenue</li>
<li>R&amp;D expenses decreased due to program prioritization and workforce reduction</li>
<li>Company in advanced stages to finalize strategic transaction by year-end</li>
</ul>
Outlook
<ul>
<li>BioAtla expects to complete a strategic partnership by year end</li>
</ul>
Result Drivers
<ul>
<li>Research and development (R&amp;D) expenses were $9.5 million for the quarter ended September 30, 2025, compared to $16.4 million for the same quarter in 2024.</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$15.78
Income mln
<h3>Q3 $13.79</h3>
Operatin mln
g
Expenses
<h3>Q3 -$13.79</h3>
Operatin mln
g Income
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 1 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Bioatla Inc is $10.00, about 93.1% above its November 12 closing price of $0.69</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

BCAB

BioAtla's Q3 net loss widened to $15.8 million due to lack of collaboration revenue. R&D expenses decreased from $16.4 million to $9.5 million due to program prioritization and workforce reduction. The company aims to finalize a strategic transaction by year-end. Analysts rate the stock as "buy" with a median price target of $10.00, significantly higher than its current price of $0.69.